Key Takeaways
- 40% YoY growth, broad-based: Revenue grew 40% YoY with top 5 and top 10 product concentration staying range-bound, signaling well-rounded growth across the portfolio.
- Full-year margin guidance raised: Operating EBITDA margin hit 25% in Q2, and full-year FY27 guidance was lifted to 24% plus, delivered despite difficult geopolitical situations.
- R&D productivity hits 5.9x: The rolling three-year R&D productivity ratio reached 5.8x, up from 3.3x, while absolute R&D spend nearly doubled over two years, building steam for revenue growth into 2029 and beyond.
- Pre-revenue assets are the waiting game: Three facilities and the Arinna acquisition are consuming capital but not yet contributing materially, with revenue timelines provided only for Indore (FY28).
- What to watch next quarter: Whether the Ambernath FDA observations close out cleanly, the pace of commercialization for approvals delayed by new export licensing rules, and any further margin expansion as low-margin product rationalization finishes.
Revenue Growth & Commercial Engine
- Sequential rebound delivered: After a pause in Q1 FY27 from tactical measures, sequential USD revenue growth returned at 5% in Q2, with management citing strong visibility in coming quarters.
- Pricing stability holds: Pricing remains stable, supported by a focus on specialty and differentiated products rather than commoditized offerings.
- Commercialization rate strong at 84%: Some approvals received in Q2 will launch in the coming quarter because revised Indian export licensing now requires the license application only after FDA approval, where previously it could be prepared in advance.
- Portfolio shifting upmarket: The mix has moved from simpler immediate-release tablets to drug-device combinations and products with sizably larger individual opportunities, while still maintaining a broad base with no hero-product concentration.
- Specialty contribution healthy: Specialty and differentiated products contributed 36% to gross profit, reinforcing the margin profile.
Parag Sancheti: "Last quarter, if you remember, we discussed that we have taken certain tactical measures that led to a pause in our sequential USD revenue growth. We had guided that the growth will be back in Q2. In that light, I am very happy to share that this quarter, our sequential USD revenue growth is 5%, and we continue to see strong visibility in the coming quarters."
Margins & Cash Flow
- Operating EBITDA at 25% in Q2: The quarter's margin expanded over Q1 FY27, driven by the near-completion of tactical low-margin product rationalization, legacy products gaining market share, healthy specialty gross margin contribution, and operating leverage, all after absorbing geopolitical costs.
- Full-year guidance raised to 24% plus: Management lifted the bar from the prior 23% plus, emphasizing the delivery came despite difficult geopolitical situations.
- Cash flow from operations strong: Nearly ₹99 crores generated in H1 FY27, supporting the investment cycle.
- Working capital improved to 117 days: The improvement from 126 days was driven by quarterly fluctuation, with normalization expected back to the 125–130 day range.
- ROACE healthy at 36%: Maintained despite roughly ₹400 crores of capital employed in pre-revenue or not-yet-materially-contributing assets.
- Tactical rationalization nearly done: The exercise to prune low-margin products is largely complete, with a few items possibly finishing in the next one or two quarters, removing a drag on margins.
Parag Sancheti: "If you remember, we last quarter said it will be about 23% plus, which is over our 22%, 23% said earlier. We are happy to report that now we are guiding it to 24% plus for the full year. Just wanted to emphasize, despite difficult geopolitical situations, we still have been able to deliver very strong EBITDA growth."
R&D Engine & Productivity
- R&D spend normalized to 10–11% of revenue: This follows a peak of 40% in FY22, while absolute R&D nearly doubled from ₹107 crores in FY24 to ₹194 crores in FY26, reflecting a maturing pipeline.
- Productivity ratio reached 5.9x: The rolling three-year R&D productivity improved from 3.3x (FY21–24) to 4.1x (FY22–25) to 5.9x (FY23–26), driven by a rigorous stage-gated approach that keeps non-productive spend low.
- Current cycle at 5.8x with room to run: The FY24–27 cycle is coming off the lowest absolute R&D spend base in recent cycles (₹218.7 crores), so the 5.8x multiple is expected to increase as revenue growth in the remaining two quarters of FY27 materializes.
- Stage-gate discipline caps waste: Significant capital is committed only after de-risking and stress-testing exercises clear stage gates; some projects do get paused or stopped later, but the rising productivity trend reflects continuous improvement in conversion efficiency.
- Revenue-per-molecule rising: The uptrend in the R&D-to-revenue ratio is a combination of revenue per molecule going up and increased efficiency in converting R&D into revenues over the years.
- Visibility into 2029 and beyond: The next two cycles (FY25–28 and FY26–29) have materially higher R&D spends already completed, building steam for an uptick in revenue growth; management described visibility on revenue growth for 2029, 2030, and beyond as "pretty strong."
Sagar Oak: "In many ways, I think we are now building up steam for that uptick that we have pointed out here. Based on this, I think we have tried to represent this a little bit differently just to bring out the various aspects of this. I hope it's easy to appreciate the visibility on revenue growth for 2029, 2030, and beyond is pretty strong for us."
Pre-Revenue Assets & Capital Deployment
- Three facilities consuming P&L without revenue: Pithampur (Indore), CSN, and New Jersey facilities are incurring expenditure routed through the P&L but are not yet generating revenue; Arinna is included in capital employed but not yet contributing meaningfully to the numerator of return on capital.
- Indore (Pithampur) timeline given: Revenue generation expected from FY28 onwards; the facility should get operationalized soon.
- CSN and New Jersey timelines withheld: Management explicitly declined to give exact timelines for CSN and New Jersey, stating for New Jersey that filings must be completed, products placed, and an FDA inspection conducted before revenue starts.
- New Jersey acquisition closed: Fixed asset base grew by ₹85 crores, with a cash payout of ₹29 crores and ₹55 crores in non-cash right-of-use.
- Arinna contributed ₹19.4 crores revenue in Q2: No material EBITDA contribution yet; management said the current phase focuses on investing behind growth and getting growth back on track, with profitability a later phase, and declined to guide on medium-term margins.
Parag Sancheti: "Just to add, Harsh, I think first, I think we, instead of guiding, we believe in doing and not talking. First, again, the focus, as Nitin said, would be on revenue and then on margins. But we still, these are early days for that business."
Regulatory & Compliance
- All four manufacturing locations inspected within six months: Ambernath, Satara, Pithampur, and New Jersey all underwent FDA inspections, with R&D sites in Canada and Thane also inspected earlier.
- Ambernath: three procedural observations: An unannounced FDA inspection in October 2026 yielded three observations on systems improvement and two on product applications under agency review; all are procedural, none relate to data integrity, and management is confident of timely resolution.
- Satara: one procedural observation: Also an unannounced October 2026 inspection; response submitted, Establishment Inspection Report awaited.
- Pithampur: two observations from July 2026: Response submitted the same month, EIR awaited.
- New Jersey and Canada clean: New Jersey inspected May 2026 pre-acquisition with EIR in place; Canada R&D site inspected earlier in 2026 with no observations and EIR in place.
Sagar Oak: "All these observations are procedural. None of them relate to data integrity. This is a very recent inspection. This inspection is literally days old, not even weeks old. We are confident of working with the regulator to close this successfully and in a timely manner."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Operating EBITDA margin | Full-year FY27 at 24% plus (raised from 23% plus) | FY27 |
| Sequential USD revenue growth | Strong visibility maintained | Coming quarters |
| Working capital normalization | 125–130 days range | Normal course |
| Low-margin product rationalization | A few remaining products to be completed | Next 1–2 quarters |
| Indore (Pithampur) revenue generation | Revenue expected | FY28 onwards |
| Ambernath FDA observations | Confident of successful, timely closure with regulator | Not specified |
| Incremental R&D spend | ₹500 crores incremental R&D to drive incremental revenues to FY30 at the productivity rate of that R&D | FY27–FY30 cycle |
| R&D spend guidance | Well on track to achieve ₹500 crores; good visibility on completing remaining spend | Next three quarters |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹577 cr, +40% YoY and +8% QoQ |
| Pre-R&D EBITDA margin | 35.8%, +170 bps YoY |
| Operating EBITDA margin | 25.0%, up from Q1 FY27; full-year guidance raised to 24%+ |
| PAT | ₹90 cr, +67% YoY; Q1 FY27 was ₹85 cr including ₹3.6 cr one-time insurance claim |
| EPS | ₹5.41, vs ₹3.47 in Q2 FY26 |
| H1 FY27 revenue | ₹1,111 cr, +45% YoY |
| H1 FY27 PAT | ₹175 cr, +80% YoY |
| Sequential USD revenue growth | 5%, rebounding after tactical measures paused growth in Q1 |
| R&D spend | ₹62 cr, 10.8% of revenue, in line with Q2 FY26 and Q1 FY27 |
| Specialty contribution to gross profit | 36% |
| ANDA approvals in Q2 | 3 |
| Commercialization rate | 84% |
| Net working capital days | 117 days, improved from 126 days as of March 2026; expected to normalize at 125–130 days |
| ROACE | 36%, in line with March 2026; ~₹400 cr of capital employed in pre-revenue assets |
| H1 FY27 net cash flow from operations | ₹99 cr |